Reuters logo
BRIEF-Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
November 6, 2017 / 2:41 AM / in a month

BRIEF-Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan

Nov 6 (Reuters) - NanoCarrier Co Ltd

* Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec (“VB-111”) in Japan

* Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan

* Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co

Source text in Japanese: goo.gl/ervaY6

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below